- Report
- February 2024
- 30 Pages
Global
From €2909EUR$3,250USD£2,541GBP
- Report
- January 2024
- 189 Pages
Global
From €6713EUR$7,500USD£5,864GBP
- Report
- February 2023
- 107 Pages
Global
From €6713EUR$7,500USD£5,864GBP
- Drug Pipelines
- April 2025
- 240 Pages
Global
From €2685EUR$3,000USD£2,346GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1343EUR$1,500USD£1,173GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1343EUR$1,500USD£1,173GBP
- Report
- July 2024
- 70 Pages
Brazil
From €4252EUR$4,750USD£3,714GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4252EUR$4,750USD£3,714GBP
- Report
- February 2024
- 80 Pages
Europe
From €4252EUR$4,750USD£3,714GBP
- Report
- February 2024
- 70 Pages
Germany
From €4252EUR$4,750USD£3,714GBP
- Report
- February 2024
- 70 Pages
Italy
From €4252EUR$4,750USD£3,714GBP
- Report
- February 2024
- 70 Pages
Oman
From €4252EUR$4,750USD£3,714GBP
- Report
- February 2024
- 70 Pages
Egypt
From €4252EUR$4,750USD£3,714GBP
- Report
- February 2024
- 70 Pages
United Kingdom
From €4252EUR$4,750USD£3,714GBP
- Report
- February 2024
- 70 Pages
France
From €4252EUR$4,750USD£3,714GBP
- Report
- February 2024
- 70 Pages
Saudi Arabia
From €4252EUR$4,750USD£3,714GBP
- Report
- February 2024
- 70 Pages
South Africa
From €4252EUR$4,750USD£3,714GBP
- Report
- February 2024
- 70 Pages
Mexico
From €4252EUR$4,750USD£3,714GBP
- Report
- February 2024
- 70 Pages
Brazil
From €4252EUR$4,750USD£3,714GBP
- Report
- February 2024
- 70 Pages
Russia
From €4252EUR$4,750USD£3,714GBP

Empagliflozin is a medication used to treat type 2 diabetes, a condition in which the body does not produce enough insulin or does not use insulin properly. It belongs to a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, which work by blocking the reabsorption of glucose in the kidneys, allowing it to be excreted in the urine. This helps to lower blood sugar levels. Empagliflozin is also used to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
Empagliflozin is marketed by several pharmaceutical companies, including Boehringer Ingelheim, Eli Lilly, and Merck. It is available in tablet form and is taken once daily. It is also available in combination with other diabetes medications, such as metformin and linagliptin. Show Less Read more